Cracking the O-GlcNAc code in metabolism

Hai-Bin Ruan1,2, Jay Prakash Singh1,2, Min-Dian Li1,2,3, Jing Wu1,2,4, and Xiaoyong Yang1,2,3

1 Program in Integrative Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06519, USA
2 Section of Comparative Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06519, USA
3 Department of Cellular and Molecular Physiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06519, USA
4 School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, Shaanxi 710049, China

Nuclear, cytoplasmic, and mitochondrial proteins are extensively modified by O-linked β-N-acetylglucosamine (O-GlcNAc) moieties. This sugar modification regulates fundamental cellular processes in response to diverse nutritional and hormonal cues. The enzymes O-GlcNAc transferase (OGT) and O-linked β-N-acetylglucosaminidase (O-GlcNACase) mediate the addition and removal of O-GlcNAC, respectively. Aberrant O-GlcNAcylation has been implicated in a plethora of human diseases, including diabetes, cancer, aging, cardiovascular disease, and neurodegenerative disease. Because metabolic dysregulation is a vital component of these diseases, unraveling the roles of O-GlcNAc in metabolism is of emerging importance. Here, we review the current understanding of the functions of O-GlcNAc in cell signaling and gene transcription involved in metabolism, and focus on its relevance to diabetes, cancer, circadian rhythm, and mitochondrial function.

Nutrient-sensing O-GlcNAc modification

Many, if not most, cytoplasmic and nuclear proteins are modified by a single O-GlcNAc moiety at serine or threonine residues, termed O-GlcNAcylation [1–3]. This dynamic and reversible modification is emerging as a key regulator of diverse cellular processes, such as signal transduction, transcription, translation, and proteasomal degradation [4,6–10]. Perturbations in protein O-GlcNAcylation are associated with a wide range of human diseases and conditions [1,4–6].

O-GlcNAcylation often occurs reciprocally or sequentially with serine/threonine phosphorylation. Growing evidence suggests that this sugar modification acts as an ‘on/off’ switch in various cellular pathways that rival phosphorylation [1,4,11]. In sharp contrast to the 428 serine/threonine kinases and ~40 phosphatases encoded in the human genome [12,13], only two single genes encode the enzymes that are responsible for cyclic O-GlcNAcylation: OGT catalyzes the addition of the GlcNAc moiety from the high-energy donor UDP-GlcNAc to target proteins at the hydroxyl groups of serine or threonine residues, whereas O-GlcNACase (OGA, NCOAT, or MGEA5) catalyzes the hydrolytic removal of the sugar moiety from proteins (Figure 1).

UDP-GlcNAc is derived from extracellular glucose through the hexosamine biosynthesis pathway (HBP). Because UDP-GlcNAc and protein O-GlcNAc levels in the cell fluctuate with the availability of glucose, free fatty acids, uridine, and the amino acid glutamine, it has long been speculated that O-GlcNAc serves as a nutrient sensor [14]. The past few years have seen significant advances in our understanding of the functions of O-GlcNAcylation in nutrient sensing and metabolic physiology. In this review, we summarize the current knowledge of transcriptional and post-translational regulation of metabolism by O-GlcNAc signaling, focusing on its relevance to diabetes, cancer, circadian rhythm, and mitochondrial function.

Hexosamine biosynthesis, O-GlcNAc modification, and insulin resistance

Nutrient excess is a major culprit of the diabetes epidemic in modern society. There is evidence that high levels of circulating glucose and free fatty acids bring about insulin resistance, a hallmark of type 2 diabetes (T2D), via the HBP [15]. Early studies show that high glucose-induced insulin resistance is associated with elevated UDP-GlcNAc levels in primary adipocytes [16]. In diabetic animals and humans there are significant increases in global O-GlcNAc levels in tissues and cells such as liver, heart, erythrocytes, and leukocytes [17,18]. Glutamate-fructose-6-phosphate amidotransferase (GFAT) is the first and rate-limiting enzyme of the HBP. Transgenic overexpression of GFAT leads to insulin resistance in muscle and adipose tissue [19,20]. In vivo administration of glucosamine, which enters the hexosamine pathway bypassing GFAT, induces insulin resistance in multiple tissues [21]. Overexpression of OGT in muscle, fat, or liver dampens insulin signaling [4,22]. These studies suggest O-GlcNAc as a nexus between nutrient flux and insulin resistance.
Surprisingly, studies on OGA have produced conflicting results. Pharmacological inhibition of OGA by PUGNAc increases global O-GlcNAC levels and causes insulin resistance in 3T3-L1 adipocytes and skeletal muscle [28,29]. However, recent studies show that more selective OGA inhibitors such as NBuGT and 6-Ac-Cas fail to induce insulin resistance in 3T3-L1 adipocytes and in rodents [30,31]. To further complicate matters, transient OGA overexpression in the liver improves insulin sensitivity in diabetic db/db mice [32]; however, reduction of O-GlcNAC levels by OGA overexpression or OGT knockdown does not prevent insulin resistance in 3T3-L1 adipocytes [33]. This OGT/OGA paradox in metabolism can also be observed in C. elegans. Forsythe et al. reported that both the Ogt- and Oga-null worms have elevated stores of glycogen and trehalose, and decreased lipid storage [34,35]. One compelling explanation for this paradox is that OGT and OGA activities are mutually dependent. Sequential activation of OGT and OGA regulates highly dynamic and cyclic cellular events to maintain metabolic homeostasis. As a result, the effects of manipulating the O-GlcNAC pathway on insulin signaling are dependent on the location, duration, and extent of the intervention.

**O-GlcNAC regulation of insulin signaling proteins**

Dynamic crosstalk between O-GlcNAcylation and phosphorylation is widely implicated in the regulation of signal transduction and gene transcription [1]. Many insulin signaling proteins, including insulin receptor (IR), insulin receptor substrate 1 (IRS1) and IRS2, phosphoinositide 3-kinase (PI3K), pyruvate dehydrogenase kinase 1 (PDK1), and the serine/threonine-specific protein kinase AKT, are known to be O-GlcNAcylated, which has been indicated as a negative regulator of insulin signal transduction (Figure 2) [4,36]. O-GlcNAcylation of IRS1 inhibits phosphorylation at Tyr 608, thereby reducing the interaction with PI3K and the activation of AKT [36,37]. Negative feedback phosphorylation of IRS1 at multiple serine residues contributes to the termination of insulin signaling. Previous work reveals that O-GlcNAcylation also inhibits IRS1 activity by increasing phosphorylation at Ser 307 and Ser 632/635 [4]. O-GlcNAcylation of AKT at Thr 305 and Thr 312 inhibits Thr 308 phosphorylation and activation by PDK1 [4,38]. Importantly, inhibition of IRS1 and AKT by O-GlcNAcylation requires the recruitment of OGT to the plasma membrane through the phosphoinositide-binding (PPO) domain, suggesting that O-GlcNAC serves as a negative feedback mechanism involved in the termination of insulin signaling [4,39].

Not only does O-GlcNAC modulate the proximal insulin signaling cascade, but also targets specific downstream pathways to elicit diverse physiological responses. As elaborated below, this coordinated action of O-GlcNAC at multiple levels is likely a fine-tuning mechanism governing metabolic homeostasis.

**O-GlcNAC regulation of glucose uptake**

Translocation of insulin-sensitive glucose transporter GLUT4 to the plasma membrane is required for insulin-induced glucose uptake into adipocytes and muscle cells that normalize blood glucose levels. There is evidence that the regulation of glucose uptake by O-GlcNAC signaling is independent of early components of insulin signaling [40]. Chen et al. found that glucosamine treatment of 3T3-L1 cells increases O-GlcNAcylation of Munc18c, an essential component of the synaptic vesicle fusion protein complex, and decreases insulin-stimulated trafficking of soluble NSF attachment protein receptor (SNARE) proteins to the plasma membrane [40]. However, it is not known whether O-GlcNAcylation of Munc18c is responsible for the defect in GLUT4 translocation induced by glucosamine.

Atypical protein kinase C (aPKC) isoforms such as PKCζ and PKCδ are also activated by insulin action, and are proposed to mediate GLUT4 trafficking through actin remodeling and other mechanisms [41,42]. aPKCs and actin are known as O-GlcNAcylated proteins [43,44]. Therefore, it is interesting to determine whether O-GlcNAcylation of aPKCs and actin directly regulates GLUT4 translocation.

**O-GlcNAC regulation of gluconeogenesis**

It has long been postulated that O-GlcNAC mediates glucose toxicity in diabetes. Diabetic liver is characterized by
uncontrolled gluconeogenesis, which contributes to hyperglycemia. Many transcription factors and cofactors that regulate gluconeogenesis are modified by O-GlcNAc. Housley et al. reported that the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) facilitates OGT targeting to forkhead box protein O1 (FOXO1), where OGT O-GlcNAcylates and activates FOXO1. Recent work by Ruan et al. reveals that OGT forms a nutrient-sensitive complex with host cell factor C1 (HCF-1) to O-GlcNAcylate PGC-1α. O-GlcNAcylated PGC-1α recruits the deubiquitinase BAP1 to remove poly-ubiquitin from PGC-1α and thereby stabilizes PGC-1α [20]. Because HCF-1 and BAP1 are highly expressed in the liver of mice fed a high-fat diet (HFD) and in db/db diabetic mice, the effectiveness of glucose to suppress gluconeogenesis is lost in those animals. Knockdown of OGT and HCF-1 improves glucose homeostasis in db/db mice [20].

It has been well-established that cAMP response element-binding protein (CREB) regulated transcription coactivator 2 (CRTC2) co-activates CREB to induce the transcription of gluconeogenic genes [45]. O-GlcNAcylation at Ser 70 and Ser 171 increases CRTC2 activity by disrupting 14-3-3 protein binding, whereas OGA overexpression in the liver disrupts O-GlcNAcylation of CRTC2 in HFD and db/db mice, and lowers the gluconeogenic profile [32]. Collectively, O-GlcNAcylation of gluconeogenic transcription factors and cofactors promotes glucose production in the liver, suggesting that pharmacological inhibition of hepatic O-GlcNAc signaling may be a new strategy for treating T2D.

**O-GlcNAc regulation of glycogen synthesis**
Glycogen synthase (GS) controls the final step of glycogen synthesis, which is stimulated by insulin through GSK3β inhibition. Activation of GS is reduced in insulin resistance and diabetes. O-GlcNAcylation of GS is associated with decreased enzymatic activity [46]. High glucose increases GS O-GlcNAcylation and suppresses GS activity, which in turn brings about blood glucose retention. This vicious cycle is another example of O-GlcNAc-mediated glucose toxicity. GSK3β is also modified by O-GlcNAc, and inhibition of GSK3β alters global O-GlcNAc levels [47,48]; however, the role of its O-GlcNAcylation has not been explored.

**O-GlcNAc regulation of lipogenesis**
Sterol regulatory element-binding protein-1c (SREBP-1c) is a master lipogenic transcription factor regulated by insulin. Fatty acid synthesis is controlled not only by insulin but also by glucose. Carbohydrate responsive element-binding protein (ChREBP) and liver X receptor (LXR) have been proposed as glucose sensors that regulate lipogenesis. Glucose regulates the levels of O-GlcNAcylation of LXR and its activity on Srebp-1c transcription, an LXR target gene [49]. ChREBP is also subject to O-GlcNAc.
modification, which stabilizes the ChREBP protein and increases its transcription activity on lipogenic genes [50]. In db/db mice, ChREBP O-GlcNAcylation is elevated in the liver, and OGA overexpression prevents hepatic steatosis in these mice. Although diabetic animals and humans show insulin resistance in the liver, hepatic lipogenic pathways are paradoxically hyperactivated. Glucose toxicity mediated by O-GlcNAcylation of key regulators of lipogenesis might be one of the mechanisms underlying such paradox.

**O-GlcNAc regulation of β cell function**

In addition to its roles in insulin signal transduction, O-GlcNAc signaling also regulates insulin production and islet survival in the pancreas. OGT is highly abundant in β cells in the islet [51] and O-GlcNAc levels in β cells are sensitive to glucose [52], implying that O-GlcNAc may function as a glucose sensor to regulate insulin secretion. Indeed, expression of the GFAT transgene in β cells increases hexosamine flux and results in hyperinsulinemia [53], whereas OGA overexpression in β cells decreases insulin mRNA levels, islet insulin content, and circulating insulin levels [54]. Neurogenic differentiation 1 (NeuroD1) and pancreatic and duodenal homeobox 1 (Pdx-1) are two β cell-specific transcription factors that have been demonstrated to play crucial roles in glucose-induced insulin gene transcription [55]. High glucose induces NeuroD1 O-GlcNAcylation and subsequent translocation into the nucleus, whereas on low glucose OGA interacts with and deglycosylates NeuroD1, and this is likely to account for NeuroD1 export into the cytoplasm [56]. Pdx-1 is also O-GlcNAcylated, which correlates with increased DNA binding ability and insulin secretion [57]. These data provide evidence for the functional roles of O-GlcNAc in insulin production and secretion.

O-GlcNAc signaling also mediates glucose toxicity in pancreatic β cells. Elevating cellular O-GlcNAc levels by the OGA inhibitor PUGNac or glucosamine infusion decreases glucose-stimulated insulin secretion and β cell survival [58–60]. However, there is evidence that the adverse effect of adenoviral overexpression of GFAT on β cell function may not be ascribed to protein O-GlcNAcylation [26,53]. It is possible that O-GlcNAc stimulates insulin secretion at physiological conditions and the onset of T2D, whereas O-GlcNAc promotes β cell dysfunction upon chronic exposure to hyperglycemia at the late stage of diabetes.

**O-GlcNAc signaling in cancer metabolism**

**O-GlcNAc as a biomarker of human cancer**

Dysregulation of O-GlcNAc signaling has been implicated in human cancer. Aberrant O-GlcNAcylation is a clinical characteristic of chronic lymphocytic leukemic patients [61]. Global O-GlcNAc levels and expression of OGT are significantly elevated in human lung and colon cancer tissues [62]. O-GlcNAc levels are also increased in hepato-cellular carcinoma tissues and, interestingly, low expression of OGA is suggested as a prognostic marker for tumor recurrence [63]. Another study suggests that urinary content of OGT and OGA may be used as a prognostic tool for bladder cancer [64]. The Reginato group described a critical role of OGT in breast and prostate cancer growth and invasion [65,66]. Therefore, protein O-GlcNAcylation is a promising biomarker and a potential driver for various human cancers.

**O-GlcNAc in transcriptional regulation of cancer metabolism**

Metabolic rewiring is an emerging hallmark of cancer [67]. Cancer cells require increased glucose uptake and aerobic glycolysis (the Warburg effect) to support rapid cell growth and proliferation [68]. This is largely achieved by reprogramming gene expression in the metabolic network. Recent studies reveal the important roles of c-Myc, Sp1, p53 and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) in this process. All of these transcription factors have been found to be modified by O-GlcNAc, and this modification can regulate their functions either positively or negatively [5,69–71]. For instance, O-GlcNAcylation of c-Myc and p53 increases the stability and activity of the proteins, whereas O-GlcNAcylation of Sp1 at the activation domain decreases its transcriptional activity [5,11]. Whether O-GlcNAcylation of these transcription factors contributes to the Warburg effect is an important topic of current investigation.

Recent evidence suggests a role for O-GlcNAc signaling in the regulation of the Warburg effect by NF-κB. The activation of the IKK–NF-κB pathway, by loss of p53, increases the rate of aerobic glycolysis and the expression GLUT3 [72]. High glucose promotes O-GlcNAcylation of IκB kinase β (IKKβ) and sustains tumor necrosis factor α (TNFα)-dependent IKKβ activity [73]. Therefore, increased glucose flux via the HBP may contribute to the Warburg effect through O-GlcNAcylation of IKKβ (Figure 3).

In addition to its role in antagonizing NF-κB, p53 also inhibits glycolysis and suppresses tumor growth through the induction of TIGAR, an inhibitor of phosphofructokinase (PFK) activity [74]. Furthermore, p53 can inhibit the pentose phosphate pathway by directly binding to and inhibiting the activity of glucose-6-phosphate dehydrogenase [75]. Mutations of p53 found in many cancers may orchestrate diverse metabolic pathways to meet the metabolic demands for tumor growth (Figure 3).

**O-GlcNAcylation of metabolic enzymes in cancer**

Almost all the glycolytic enzymes are O-GlcNacylated. A recent study by Yi et al. reveals that O-GlcNAcylation of PFK-1 decreases its enzymatic activity, thereby decreasing overall glycolytic flux and diverting glucose flux to the pentose phosphate pathway (Figure 3) [8]. This is critical for reducing oxidative stress and supporting rapid cell growth [8]. This study summons more effort to investigate the regulatory roles of direct O-GlcNAcylation of metabolic enzymes in normal physiology and cancer. This may help identify an Achilles’ heel of cancer metabolism that could be exploited in future therapeutic interventions.

**O-GlcNAc signaling links the circadian clock to metabolism**

The circadian clock (Box 1) is emerging as an important mechanism governing metabolism [76]. Many metabolic
processes, such as hormone secretion, nutrient uptake, gluconeogenesis, and oxidative phosphorylation, have a daily cycle [77–79] driven by cell-autonomous clock oscillators in the brain and metabolic tissues [80,81]. Misalignment of the internal rhythm with the environmental daily cycle contributes to metabolic disorders and cancer [77,82,83].

Growing evidence indicates that O-GlcNAcylation mediates the circadian regulation of metabolism. As discussed in previous sections, O-GlcNAcylation fine-tunes nutrient/hormonal signaling pathways. It is possible that circadian clocks drive daily changes in protein O-GlcNAcylation to modulate energy metabolism. Gene expression profiles show that both Ogt and Oge transcripts exhibit circadian rhythm in metabolic tissues (http://bioinf.itmat.upenn.edu/circa). The circadian expression of Gfat-1 in the fat body of fruit flies has been documented [84]. Durgan et al. reported that protein O-GlcNAcylation in the heart changes in a daily manner and is modulated by the heart clock [85]. Recently, Kaasik et al. identified OGT as a direct substrate of GSK3β that exhibits circadian kinase activity in vivo [86], further supporting the idea of circadian changes in protein O-GlcNAcylation. Although the metabolic significance of circadian O-GlcNAcylation is largely unknown, Liet et al. demonstrated that genetic manipulation of hepatic OGT expression in mice results in aberrant rhythms of glucose homeostasis [87]. These findings strongly argue for a role of protein O-GlcNAcylation in linking the circadian clock to metabolic outputs.

O-GlcNAcylation also acts as an input pathway to reset the clock. Studies in the past decade have identified many nutrient-responsive proteins as clock regulators [88], which reset the circadian rhythm according to the feeding/fasting cycle in metabolic tissues (Box 1). As an important nutrient-sensing mechanism, O-GlcNAcylation may modify clock proteins to control the internal time. Early studies in Arabidopsis thaliana have shown that the plant OGT (SPINDLY) regulates circadian rhythms [89]. Durgan et al. observed O-GlcNAcylation of two clock proteins and the phase-resetting role of PUGNAc [85], which raises the question as to how O-GlcNAc modulates the function of clock proteins and circadian physiology. To date, circadian changes in O-GlcNAcylation have been found on BMAL1 [85,87,90], CLOCK/dClk [86,87], and PER/dPer [85,86,91].

Figure 3. Regulation of cancer metabolism by the hexosamine/O-GlcNAc pathway. In normal cells, p53 suppresses glycolysis by inducing expression of TIGAR and inhibiting expression of glycolytic genes such as hexokinase II, phosphoglycerate mutase, and glucose transporter 3 (GLUT3). p53 also inhibits the diversion of glucose flux to the anabolic pentose phosphate pathway (PPP) by binding to and inhibiting glucose-6-phosphate dehydrogenase (G6PD). p53 loss-of-function in tumor cells increases glucose uptake, aerobic glycolysis, and PPP flux. PPP flux produces reducing agents for macromolecule biosynthesis and reactive oxygen species (ROS) neutralization. Two to five percent of glucose is shunted to the HBP that produces UDP-GlcNAc, a substrate for OGT. OGT inhibits ubiquitin-mediated degradation of p53 by direct O-GlcNAcylation. OGT also potentiates NF-κB signaling by O-GlcNAcylation and activation of IKKα, which triggers phosphorylation of IκBα and release of NF-κB to the nucleus to promote transcription of glucose transporters and HIF-1. HIF-1 increases the expression of glycolytic genes to promote tumor growth. Finally, O-GlcNAcylation of the critical glycolytic enzyme PFK-1 reduces its enzymatic activity (red arrow) and redirects glucose flux through the PPP, thereby conferring a selective growth advantage on cancer cells.
Mitochondrial O-GlcNAcylation in metabolic regulation

Mitochondrial OGT (mOGT) arises from a single Ogt gene by alternative splicing that generates a unique N-terminus containing mitochondrial targeting sequence and a membrane-spanning helix (Figure 1) [96,97]. Its nine tetrastricopeptide repeat (TPR) motifs through the C-terminus are identical to those of ncOGT [96]. Overexpression of mOGT is highly cytotoxic and triggers apoptosis [98,99]. This impedes research on mitochondrial O-GlcNAcylation and its function.

Early studies reported that the levels of mitochondrial O-GlcNAcylation were very low [47,96]. However, increasing evidence suggests pervasive mitochondrial O-GlcNAcylation [100–103]. This modification may either protect or perturb mitochondrial function. O-GlcNAcylation of the voltage-dependent anion channel (VADC) in cardiac myocytes can preserve mitochondrial integrity by interfering with mitochondrial permeability transition pore formation induced by Ca\(^{2+}\) overload and oxidative stress [101,102]. Increased O-GlcNAcylation of the respiratory chain complex I, III, and IV impairs mitochondrial function in cardiac myocytes [103]. Increased O-GlcNAcylation of dynamin-related protein 1 (DRP1) induces translocation of DRP1 from the cytoplasm to mitochondria, and this increases mitochondrial fragmentation and decreases mitochondrial membrane potential [104]. Furthermore, low running-capacity rats exhibit increased O-GlcNAcylation of cardiac proteins including mitochondrial Complex I and IV, VDAC, and sarco/endoplasmic reticulum Ca\(^{2+}\)-ATPase (SERCA), and this may contribute to progressive mitochondrial dysfunction and the pathogenesis of insulin resistance [105]. A large number of mitochondrial proteins associated with OGT were recently identified via a proteomic approach, further suggesting the importance of OGT to mitochondrial function [20].

Although the repertoire of mitochondrial O-GlcNAc targets is rapidly expanding, many critical questions remain to be answered. UDP-GlcNAc is likely limited in mitochondria, but how it transports into mitochondria remains unknown. Although scarce evidence shows direct interaction between mOGT and mitochondrial proteins, it does not exclude the possibility that those proteins may be O-GlcNAcylated in the cytoplasm before entering mitochondria. Despite the fact that OGA activity is detectable in purified mitochondria [103], mitochondrial OGA proteins have not been identified. Finally, whether O-GlcNAcylation of mitochondrial proteins responds to nutritional and hormonal signals, and regulates intermediary metabolism, is poorly understood.

Concluding remarks

The past decade has witnessed significant advances in our understanding of the versatile roles of post-translational modifications, such as phosphorylation, acetylation, methylation, and ubiquitination, in fundamental cellular processes. Despite the discovery of O-GlcNAc modification three decades ago, we are just beginning to unravel its biological functions at levels ranging from protein structure and interaction to cell signaling and gene regulation to physiology and metabolism (Box 2). Accumulating evidence suggests that O-GlcNAc acts as a nutrient sensor.
that couples systemic metabolic status to cellular regulation of signal transduction, transcription, and protein degradation. The best established is O-GlcNAcylation regulation of insulin signaling proteins and transcriptional regulators involved in glucose and lipid metabolism. Only recently, O-GlcNAcylation of transcription factors involved in cancer metabolism and circadian rhythm is being appreciated. Because metabolic enzymes are the prevalent targets of O-GlcNAcylation in the cytoplasm, nucleus, and mitochondria, elucidating the roles of O-GlcNAcylation of metabolic enzymes in regulating metabolic flux and epigenetics will be an exciting area of research. In light of the emerging links between protein O-GlcNAcylation and diabetes, cancer, and aging, as well as cardiovascular and neurodegenerative diseases, uncovering functions and mechanisms of O-GlcNAc signaling would be crucially important for exploring O-GlcNAc as a therapeutic target for these diseases (Box 2).

Acknowledgments

This work was supported by the National Institutes of Health (R01 DK089098, P01 DK057751), American Diabetes Association, and Ellison Medical Foundation to X.Y., the Brown-Coxe fellowship to H.R., the China Scholarship Council-Yale World Scholars fellowship to M.L., and the Xi’an Jiaotong University international cooperation grant to J.W.

References

7 Zhang, F. et al. (2003) O-GlcNac modification is an endogenous inhibitor of the proteasome. Cell 115, 715–725
8 Yi, W. et al. (2012) Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 337, 975–980
20 Ruan, H.B. et al. (2012) O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1alpha stability. Cell Metab. 16, 220–237
32 Dentin, R. et al. (2008) Hepatic glucose sensing via the CREB coactivator CRT2C. Science 319, 1402–1405


57 Gao, Y. et al. (2003) The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosaminyltransferase and this modification is correlated with its DNA binding activity and insulin secretion in minPb beta-cells. Arch. Biochem. Biophys. 415, 155–163.
